Matthieu Stoll

Matthieu Stoll

Auto-generated profile, based on publicly available information

Matthieu Stoll

FSMR SENSGENE, Coordination Center, Hôpitaux Universitaires de Strasbourg, Strasbourg, France

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 May 2026 in JMIR Medical Informatics
Verified
Journal Article
Open access
CMCamille Beluffi Marin
Camille Beluffi Marin
MOMarilyne Oswald
Marilyne Oswald
LRLaura Ratenet
Laura Ratenet
MSMatthieu Stoll
Matthieu Stoll
KCKirsley Chennen
Kirsley Chennen
HDHélène Dollfus
Hélène Dollfus
Background: In France, clinical data on rare diseases are primarily collected through BaMaRa (Base Maladies Rares), a software platform used by national expert centers to populate the BNDMR (Banque Nationale de Données Maladies Rares), the French national rare disease data warehouse. BaMaRa ensures standardized and structured data collection across all rare disease networks, with a focus on care coordination and epidemiological reporting. In 2024, FREDD (French Rare Eye Disease Database), a health data warehouse dedicated to rare eye diseases, was developed within the framework of the third French National Rare Disease Plan by the SENSGENE sector. Despite overlapping datasets, there is no native interoperability between BaMaRa and FREDD, requiring the development of a dedicated, traceable pipeline to transform BaMaRa exports into data suitable for inclusion in FREDD. This transformation involves complex business rules to address structural, semantic, and specific differences between the two systems. Objective: This study aims to describe the design and implementation of a robust data transformation pipeline that enables the automated conversion of BaMaRa clinical records into a structured dataset aligned with the FREDD data model. The primary goal is to ensure that the data remain semantically consistent and reusable for the secondary use of health data. Methods: We developed a Python-based application called FREDDEX that integrates several configuration files and encodes the domain-specific business rules required to align BaMaRa data with the FREDD schema. These rules include patient filtering, mapping of variable names and values, management of multisource redundancy, and prevention of overwriting. The system was designed to be modular, auditable, and usable by clinical data managers with minimal technical expertise. Results: FREDDEX was tested and validated on a BaMaRa export of 1000 real patients from Strasbourg University Hospital. The tool successfully filtered and created 641 patient profiles in FREDD, with a 99% success rate for attempted imports and full concordance (100%) for directly mapped and inferred variables. Genetic data reconstruction was confirmed on a random sample of 30 patients with genetic information, showing 100% accuracy, and multidiagnostic blocks were correctly handled in all manually reviewed cases. Beyond validation, FREDDEX processed up to 5000 patient records, enabling the rapid onboarding of new clinical sites and significantly reducing manual curation time, while runtime and memory usage demonstrated near-linear scaling. Importantly, the tool established a facilitated reproducible framework adaptable to other rare disease contexts and interoperable with national and European platforms, such as European Reference Network-EYE. Conclusions: This work demonstrates that transforming structured national rare disease registry data into a research-oriented health data warehouse is feasible when clinical business rules are explicitly formalized within an auditable extract-transform-load framework. Beyond the FREDD use case, this approach illustrates how interoperability between care-based and research infrastructures can be operationalized in rare diseases while preserving semantic integrity and regulatory compliance.

25 August 2026 in JMIR Medical Informatics
Verified
Journal Article
Open access
CMCamille Beluffi Marin
Camille Beluffi Marin
MOMarilyne Oswald
Marilyne Oswald
LRLaura Ratenet
Laura Ratenet
MSMatthieu Stoll
Matthieu Stoll
KCKirsley Chennen
Kirsley Chennen
HDHélène Dollfus
Hélène Dollfus
Background: Rare eye diseases are characterized by low prevalence, clinical heterogeneity, and fragmented data collection, which limit the reliability of analysis results and multicenter research. In France, the development of health data warehouses is strictly regulated by national data protection authorities. While international initiatives aim to harmonize rare disease registries, capturing hyperspecialized, multimodal clinical records and ophthalmology-specific imaging within a fully compliant and sustainable infrastructure remains a major operational challenge. Objective: This study aims to describe the methodological framework, regulatory implementation, and early operational outcomes of FREDD (French Rare Eye Disease Database), a national interoperable health data warehouse dedicated to rare eye diseases, and to analyze its key success factors, technical bottlenecks, and long-term financial sustainability models. Methods: Developed under the oversight of the French National Institute of Health and Medical Research (Institut national de la santé et de la recherche médicale; INSERM), the warehouse implements a centralized 3-layer architecture encompassing data collection, processing, and research reuse environments. The dataset extends the national minimum rare disease dataset with detailed ophthalmology variables structured through a dynamic electronic case report form, as well as a dedicated collection of ophthalmic images. Interoperability is achieved using international domain ontologies and a custom parsing tool (FREDDEX) designed to automatically prefill clinical data from the existing French national rare disease registry. Centralized monitoring, data curation, and cross-center quality tracking are driven by a dedicated in-house dashboard (FREDDIn [FREDD Insights]), while unstructured retinal images are processed through a standardized pseudonymization and human-verified validation pipeline. Implementation (Results): Official regulatory authorization was obtained in April 2024, and active data collection began in March 2025 across 5 pilot expert centers, focusing its initial phase on inherited retinal dystrophies, primarily retinitis pigmentosa. Over a 1-year period, the warehouse successfully integrated clinical data from 1649 patients—representing 20.3% of all retinitis pigmentosa cases registered nationally—and accumulated more than 10,000 ophthalmic images. The centralized dashboard maintained an overall data inconsistency rate of approximately 7%, chiefly reflecting logical dependencies. Among the included patients, 36.7% (605/1649) patients had associated imaging data, with fundus photography being the most widely available modality (768/1649, 46.6%). Conclusions: The implementation of this database demonstrates that a highly specialized, multimodal health data warehouse can be successfully deployed in a highly regulated environment when regulatory anticipation, governance formalization, and technical flexibility are addressed in parallel. While initial development was supported by institutional grants, long-term sustainability will require a structured cost-recovery model. Future milestones will focus on expanding center coverage nationwide, refining image annotation frameworks for AI readiness, and deploying automated export pathways toward European registries.